company background image
PRPH

ProPhase Labs NasdaqCM:PRPH Stock Report

Last Price

US$11.07

Market Cap

US$177.2m

7D

4.8%

1Y

118.3%

Updated

28 Sep, 2022

Data

Company Financials +
PRPH fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance3/6
Financial Health5/6
Dividends2/6

PRPH Stock Overview

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States.

ProPhase Labs Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ProPhase Labs
Historical stock prices
Current Share PriceUS$11.07
52 Week HighUS$15.25
52 Week LowUS$4.93
Beta-0.42
1 Month Change-4.65%
3 Month Change-12.70%
1 Year Change118.34%
3 Year Change461.93%
5 Year Change440.00%
Change since IPO2,114.00%

Recent News & Updates

Aug 10

ProPhase Labs Q2 2022 Earnings Preview

ProPhase Labs (NASDAQ:PRPH) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is $0.16 and the consensus Revenue Estimate is $23.32M (+155.1% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward. Revenue estimates have seen 1 upward revision and 0 downward.

Shareholder Returns

PRPHUS PharmaceuticalsUS Market
7D4.8%-0.3%-5.8%
1Y118.3%4.2%-22.1%

Return vs Industry: PRPH exceeded the US Pharmaceuticals industry which returned 4.2% over the past year.

Return vs Market: PRPH exceeded the US Market which returned -22.1% over the past year.

Price Volatility

Is PRPH's price volatile compared to industry and market?
PRPH volatility
PRPH Average Weekly Movement13.2%
Pharmaceuticals Industry Average Movement11.5%
Market Average Movement6.9%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: PRPH is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: PRPH's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1989129Ted Karkushttps://www.prophaselabs.com

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.

ProPhase Labs Fundamentals Summary

How do ProPhase Labs's earnings and revenue compare to its market cap?
PRPH fundamental statistics
Market CapUS$177.19m
Earnings (TTM)US$26.55m
Revenue (TTM)US$131.25m

6.7x

P/E Ratio

1.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PRPH income statement (TTM)
RevenueUS$131.25m
Cost of RevenueUS$55.26m
Gross ProfitUS$75.99m
Other ExpensesUS$49.44m
EarningsUS$26.55m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.66
Gross Margin57.90%
Net Profit Margin20.23%
Debt/Equity Ratio11.7%

How did PRPH perform over the long term?

See historical performance and comparison

Dividends

2.7%

Current Dividend Yield

n/a

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is PRPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PRPH?

Other financial metrics that can be useful for relative valuation.

PRPH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.2x
Enterprise Value/EBITDA3.9x
PEG Ratio-0.1x

Price to Earnings Ratio vs Peers

How does PRPH's PE Ratio compare to its peers?

PRPH PE Ratio vs Peers
The above table shows the PE ratio for PRPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average30.4x
JUSH.F Jushi Holdings
6x-69.9%US$249.0m
SHWZ Medicine Man Technologies
5.7xn/aUS$57.2m
MRMD MariMed
98.2xn/aUS$149.3m
SLGL Sol-Gel Technologies
12.1x-3.4%US$115.9m
PRPH ProPhase Labs
6.7x-53.9%US$177.2m

Price-To-Earnings vs Peers: PRPH is good value based on its Price-To-Earnings Ratio (6.7x) compared to the peer average (30.4x).


Price to Earnings Ratio vs Industry

How does PRPH's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Earnings vs Industry: PRPH is good value based on its Price-To-Earnings Ratio (6.7x) compared to the US Pharmaceuticals industry average (12.6x)


Price to Earnings Ratio vs Fair Ratio

What is PRPH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PRPH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio6.7x
Fair PE Ratio8.6x

Price-To-Earnings vs Fair Ratio: PRPH is good value based on its Price-To-Earnings Ratio (6.7x) compared to the estimated Fair Price-To-Earnings Ratio (8.6x).


Share Price vs Fair Value

What is the Fair Price of PRPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PRPH ($11.07) is trading below our estimate of fair value ($35.2)

Significantly Below Fair Value: PRPH is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Future Growth

How is ProPhase Labs forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-53.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PRPH's earnings are forecast to decline over the next 3 years (-53.9% per year).

Earnings vs Market: PRPH's earnings are forecast to decline over the next 3 years (-53.9% per year).

High Growth Earnings: PRPH's earnings are forecast to decline over the next 3 years.

Revenue vs Market: PRPH's revenue is expected to decline over the next 3 years (-24.7% per year).

High Growth Revenue: PRPH's revenue is forecast to decline over the next 3 years (-24.7% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PRPH's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has ProPhase Labs performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


61.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PRPH has a high level of non-cash earnings.

Growing Profit Margin: PRPH became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: PRPH has become profitable over the past 5 years, growing earnings by 61.6% per year.

Accelerating Growth: PRPH has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: PRPH has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).


Return on Equity

High ROE: PRPH's Return on Equity (39%) is considered high.


Discover strong past performing companies

Financial Health

How is ProPhase Labs's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: PRPH's short term assets ($70.3M) exceed its short term liabilities ($16.7M).

Long Term Liabilities: PRPH's short term assets ($70.3M) exceed its long term liabilities ($13.1M).


Debt to Equity History and Analysis

Debt Level: PRPH has more cash than its total debt.

Reducing Debt: Insufficient data to determine if PRPH's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: PRPH's debt is well covered by operating cash flow (186.8%).

Interest Coverage: PRPH's interest payments on its debt are well covered by EBIT (163.4x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is ProPhase Labs's current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


2.71%

Current Dividend Yield

Dividend Yield vs Market

ProPhase Labs Dividend Yield vs Market
How does ProPhase Labs dividend yield compare to the market?
SegmentDividend Yield
Company (ProPhase Labs)2.7%
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast in 3 Years (ProPhase Labs)n/a

Notable Dividend: PRPH's dividend (2.71%) is higher than the bottom 25% of dividend payers in the US market (1.67%).

High Dividend: PRPH's dividend (2.71%) is low compared to the top 25% of dividend payers in the US market (4.69%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, PRPH has been paying a dividend for less than 10 years.

Growing Dividend: PRPH's dividend payments have increased, but the company has only paid a dividend for 3 years.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (36.4%), PRPH's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Ted Karkus (63 yo)

13.25yrs

Tenure

US$941,400

Compensation

Mr. Ted William Karkus has served as the Chief Executive Officer of ProPhase Labs, Inc. since June 2009. Mr. Karkus founded 2001 Forrester Financial LLC and served as its Managing Member. He is a Managemen...


CEO Compensation Analysis

Ted Karkus's Compensation vs ProPhase Labs Earnings
How has Ted Karkus's remuneration changed compared to ProPhase Labs's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

US$27m

Mar 31 2022n/an/a

US$18m

Dec 31 2021US$941kUS$590k

US$6m

Sep 30 2021n/an/a

-US$5m

Jun 30 2021n/an/a

-US$2m

Mar 31 2021n/an/a

-US$460k

Dec 31 2020US$445kUS$125k

-US$2m

Sep 30 2020n/an/a

-US$2m

Jun 30 2020n/an/a

-US$2m

Mar 31 2020n/an/a

-US$3m

Dec 31 2019US$249kUS$125k

-US$3m

Sep 30 2019n/an/a

-US$3m

Jun 30 2019n/an/a

-US$4m

Mar 31 2019n/an/a

-US$3m

Dec 31 2018US$2mUS$210k

-US$2m

Sep 30 2018n/an/a

-US$1m

Jun 30 2018n/an/a

-US$826k

Mar 31 2018n/an/a

-US$1m

Dec 31 2017US$2mUS$675k

-US$2m

Sep 30 2017n/an/a

-US$3m

Jun 30 2017n/an/a

-US$3m

Mar 31 2017n/an/a

-US$3m

Dec 31 2016US$851kUS$675k

-US$4m

Sep 30 2016n/an/a

-US$3m

Jun 30 2016n/an/a

-US$2m

Mar 31 2016n/an/a

-US$2m

Dec 31 2015US$861kUS$675k

-US$2m

Compensation vs Market: Ted's total compensation ($USD941.40K) is below average for companies of similar size in the US market ($USD1.69M).

Compensation vs Earnings: Ted's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: PRPH's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: PRPH's board of directors are seasoned and experienced ( 10.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NasdaqCM:PRPH Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
10 Mar 22BuyUS$4,672Jason BarrIndividual721US$6.48

Ownership Breakdown

What is the ownership structure of PRPH?
Owner TypeNumber of SharesOwnership Percentage
Institutions2,051,64512.8%
Individual Insiders3,228,28320.2%
General Public10,726,29467.0%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.6%.


Top Shareholders

Top 25 shareholders own 32.13% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
18.05%
Ted Karkus
2,888,609$32.0m10.88%no data
3.75%
The Vanguard Group, Inc.
600,209$6.6m17.09%no data
1.71%
Louis Gleckel
273,840$3.0m0%no data
1.57%
Renaissance Technologies LLC
250,610$2.8m12.58%no data
0.92%
Avidian Wealth Solutions, LLC
146,934$1.6m4.7%0.11%
0.89%
Perritt Capital Management, Inc.
142,900$1.6m-31.43%0.92%
0.85%
Columbia Management Investment Advisers, LLC
136,534$1.5m-1.02%no data
0.7%
Geode Capital Management, LLC
111,806$1.2m5.62%no data
0.45%
Hillsdale Investment Management Inc.
71,499$791.5k0%0.05%
0.35%
GlobeFlex Capital LP
56,175$621.9k0%0.1%
0.3%
American Century Investment Management Inc
47,903$530.3k612.31%no data
0.27%
BNY Mellon Asset Management
42,711$472.8k-0.19%no data
0.23%
State Street Global Advisors, Inc.
36,763$407.0k18.35%no data
0.22%
Marshall Wace LLP
35,122$388.8k0%no data
0.22%
Monica Brady
34,872$386.0k369.47%no data
0.21%
Virtu Financial LLC, Asset Management Arm
34,275$379.4k0%0.03%
0.21%
BlackRock, Inc.
33,558$371.5k29.97%no data
0.21%
First Trust Advisors LP
33,342$369.1k0%no data
0.19%
Jason Barr
30,962$342.7k0%no data
0.17%
Merrill Lynch & Co. Inc., Banking Investments
27,101$300.0k-7.66%no data
0.16%
Millennium Management LLC
25,562$283.0k0%no data
0.14%
Dimensional Fund Advisors LP
23,021$254.8k0%no data
0.12%
Acadian Asset Management LLC
19,883$220.1k0%no data
0.12%
Quadrature Capital Limited
19,487$215.7k0%0.01%
0.12%
Northern Trust Global Investments
18,446$204.2k-2.23%no data

Company Information

ProPhase Labs, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: ProPhase Labs, Inc.
  • Ticker: PRPH
  • Exchange: NasdaqCM
  • Founded: 1989
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$177.189m
  • Shares outstanding: 16.01m
  • Website: https://www.prophaselabs.com

Number of Employees


Location

  • ProPhase Labs, Inc.
  • 711 Stewart Avenue
  • Suite 200
  • Garden City
  • New York
  • 11530
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PRPHNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 1992

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/28 00:00
End of Day Share Price2022/09/28 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.